Türkiye İlaç ve Tıbbi Cihaz Kurumu

Similar documents
NEW AND GLOBAL + OLD APPROACH PRODUCT LEGISLATION: A. Standard questionnaire to be filled for each sector individually:

Conducting Clinical Trials in Turkey

Bilgehan Karadayı Turkish MoH

Framework for rapid assessment of the pharmaceutical sector in a given country

The objectives of the Sri Lankan National Medicinal Drug Policy are

Interested in Learning More about Pharmacy?

Can a tulip become a rose?

Health Care Services

S P E C I A L I S T A N D M A S T E R S T U D I E S

THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA

ARMENIA PHARMACEUTICAL COUNTRY PROFILE

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Turkey

healthcare associated infection 1.2

Assessment of Drug Utilization Patterns in Some Health Insurance Outpatient Clinics in Alexandria 1Ibrahem, Samaa Zenhom; 1Amer, N.; 2Ghoneim, M.

Kāhuna Lapaÿau Healers & Food Science

Masters Learning mode (Форма обучения)

HEALTHCARE FINANCING REFORM: THE CASE in TURKEY. Prof. Ahmet Burcin YERELI. Department of Public Finance,

How To Improve The Health Care System In Ohio

Five-Year Strategic Plan ( ) HEALTH INFORMATION SYSTEM MYANMAR

Medical Technologies Market in Turkey

SUPPLY SIDE OF HEALTH INSURANCE SYSTEM IN INDONESIA

Overview of the national laws on electronic health records in the EU Member States National Report for Lithuania

SWECARE FOUNDATION. Uniting the Swedish health care sector for increased international competitiveness

How To Write An Eprescription In Dubai

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

Evaluating Impact: Turning Promises into Evidence

Medication Therapy Management Program. A service for better understanding and managing the drugs you take at no additional cost to you.

Health systems approach to improving the use of medicines in the S. E. Asian Region. Holloway KA, Weerasuriya K, Abayawardana C, Ahmed S, Rahman F

Guidance on UK medical education delivered outside the UK. Introduction. Purpose of guidance

Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015

Greek ehealth Strategy under public consultation

Annex 7 Guidelines for the preparation of a contract research organization master file

5 Health Care Pathways

Healthcare Information Technology Infrastructures in Turkey

Agency # REGULATION 9 PHARMACEUTICAL CARE/PATIENT COUNSELING

SADC GUIDELINES ON IMPORT AND EXPORT PROCEDURES FOR PHARMACEUTICAL PRODUCTS

QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES

COUNTRY REPORT: CAMBODIA Sophal Oum, MD, MTH, DrPH, Deputy Director-General for Health

08 - MEDICAL ADMINISTRATION

Transforming the pharmacy into a strategic asset

Digitization of Healthcare Information System (CSIOZ)

Αthina Triantafyllidi, Director IDIKA S.A

The Medical Device Industry in Korea: Strategies for Market Entry

2014, That Was The Year That Was Greg Baran, RPh, MA, FMPA Baran Consulting LLC

Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:

Practice Direction Clinical Practice Pharmacies

EHR central system advantages and disadvantages, the case of Estonia. Estonian E-health Foundation Raul Mill

Social health insurance in Belgium. Charlotte Wilgos & Thomas Rousseau

Global Policy on Interactions with Healthcare Professionals

The agency perspective

Zambia UK Health Workforce Alliance & Zambia Ministry of Health Conference

FINLAND ON A ROAD TOWARDS A MODERN LEGAL BIOBANKING INFRASTRUCTURE

BIOLOGICAL SCIENCES. What can I do with this degree?

Introduction of a Standard Drug Formulary in Hospital Authority

A Study on Factors affecting Productivity of Outpatient Pharmacy of a Corporate Hospital

U.S. Bureau of Labor Statistics. Pharmacy Tech

MYANMAR HEALTH CARE SYSTEM

Continuing education for community pharmacists in Denmark the case of Master of Drug Management

REDUCING HEALTH INEQUALITIES IN TURKEY WITHIN THE SCOPE OF HEALTH TRANSFORMATION PRORAMME

Introduction to the CTA & NDA process in China

Manchester Pharmacy School.

MSD Information Technology Global Innovation Center. Digitization and Health Information Transparency

DRUG SAFETY AND HUMAN RESOURCES SUBSECTORS ANALYSIS

QUM and Continuity of Care A Prescribed Medicines Services and Programs

Components of Geonomics and Bio-Informatics

Pharmacy Benefit Managers: What we do

REGULATION OF HEALTH STANDARDS IN SPORTS ACTIVITIES AND THE FIGHT AGAINST DOPING

USP CONVENTION MEMBERS BY WORLD REGION

BIOPHARMACEUTICAL INDUSTRY IMPACT REPORT: Florida PRESENTED BY:

Drug and Alcohol Testing of Doctors. Medical Negligence Lawsuits. Initiative Statute.

River Valley Therapy & Sports Medicine, Inc. Notice of Privacy Practices

APIFARMA PORTUGUESE PHARMACEUTICAL INDUSTRY ASSOCIATION

Introduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors.

Policy Briefing. Health Structures in Ireland, North and South

French pharmaceutical system Focus on pricing and reimbursement

Ensuring Best Practice in the Notification of Prescription Medical Product Discontinuations

Public Administration Institute For Turkey And the Middle East. Member of: International Institute of Administrative Sciences IIAS.

Healthcare, Regulatory and Reimbursement Landscape - Australia

WHO Medicines Strategy. Countries at the core World Health Organization

AMERICAN PSYCHOLOGICAL ASSOCIATION

Information Governance and Management Standards for the Health Identifiers Operator in Ireland

Drug and Alcohol Testing of Doctors. Medical Negligence Lawsuits. Initiative Statute.

Structure of State Regulatory Authorities REGISTRATION CERTIFICATE ISSUING AUTHORITY ROSZDRAVNADZOR

REGULATORY REQUIREMENTS OF PHARMACOVIGILANCE SYSTEM AND ITS COMPARISON IN INDIA AND USA

MINISTRY OF HEALTH AND SOCIAL SERVICES NATIONAL PHARMACEUTICAL MASTER PLAN

100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS

Transcription:

w w w. t i t c k. g o v. t r TURKISH MEDICINES AND MEDICAL DEVICES AGENCY Gulsen ONER, Pharm. M.Sc. Melda KECIK, Pharm. M.Sc. WHO Technical Briefing Seminar, November 2014

OUTLINE I. About Turkey II. About Turkish Medicines and Medical Devices Agency (TMMDA) III. Rational Use of Medicines : Activities 2

ABOUT TURKEY 3

DEMOGRAPHIC & ECONOMIC INDICATORS - 2013 Population * 76.7 million Median Age * 30.4 GDP * 820 Billion $ (At current prices) GDP Per Capita ** $10,946 *TurkStat, Turkey s Statistical Yearbook, 2013 **http://data.worldbank.org/indicator/ny.gdp.pcap.cd 4

HEALTH TRANSFORMATION PROGRAM (HTP) IN HTP was introduced in response to a number of problems At the turn of the millennium the performance of Turkey s health sector: Health outcomes Financial protection Patient satisfaction Financial sustainability TURKEY, SINCE 2003 5

HEALTH TRANSFORMATION PROGRAM (HTP) Efficiency Quality Access HTP aimed to organize, fund and provide health care services in an effective, efficient and equitable manner. 6

ACHIEVEMENTS (2000-2012) 71 76.8 74.8 64 40 39.5 31.6 27.6 11.6 11 15.4 15.4 expectation of life at birth (year)* infant mortality rate (%)* U5MR (per 1000 live births)** maternal mortality (per 100000 live births)** OOP expenditure as a share of total health expenditure (%)** health services satisfaction rate (satisfied)* *Turkish Statistical Institute **Health Statistics Yearbook 2012/General Directorate of Health Research 7

DRUG REGULATIONS Turkish Medicines and Medical Devices Agency (TMMDA) Social Security Institution (SSI) 8

ABOUT US 9

TURKISH MEDICINES AND MEDICAL DEVICES AGENCY General Directorate of Pharmaceuticals & Pharmacy (February 1946) Turkish Medicines & Medical Devices Agency (Affiliated to MoH since 2012) 10

TURKISH MEDICINES AND MEDICAL DEVICES AGENCY The Turkish Medicines and Medical Devices Agency (TMMDA) is the governmental regulatory authority on human medicinal products, medical devices and cosmetics in Turkey. TMMDA is responsible for; o regulation o evaluation and o monitoring all these product groups 11

PRESIDENT Department of Legal Consultancy Office of Executive Secretary Department of Strategy Development Scientific Advisory Committee Vice Presidency of Support and Laboratory Services Vice Presidency of Economic Assessments and Information Management Vice Presidency of Inspectorate Vice Presidency of Medicinal Products and Pharmacy Vice Presidency of Medical Devices and Cosmetics Department of Human Resources Department of Economic Assessments Department of Medicine Inspection Department of Medicinal Products Marketing Authorization Department of Medical Devices Registration and Coordination Department of Administrative and Financial Affairs Department of Rational Drug Use and Drug Supply Management Department of Medical Devices Inspection Department of Clinical and Technological Assessment Department of Medical Devices Sectoral Services Department of Analysis and Control Laboratories Department of Information Systems Department of Cosmetics Inspection Department of Pharmacies and Licencing of Pharmaceutical Warehouses Department of Medical Devices Notified Body and Clinical Trials Department of International Relations Administrative and Fiscal Inspection Department of Clinical Trials Department of Cosmetics Quality Management Department of Risk Management 12

The TMMDA s MAIN ACTIVITIES I Marketing authorization of local/imported medicinal products Marketing authorization application dossier; A. new medicinal product B. generic medicinal product C. biological and biotechnological medicinal product D. traditional herbal medicinal product E. advance therapy medicinal product 13

Medical devices The TMMDA s MAIN ACTIVITIES - II Registration to Republic of Turkey Medical Devices and Drugs Databank (TITUBB) Cosmetic products Notification 14

The TMMDA s MAIN ACTIVITIES - III Analysis and control process of medicines, medical devices, cosmetics, biotechnological products, enteral nutrition products, biological products GxP inspections & Certification of manufacturing sites of human medicinal products Market surveillance of medical devices & cosmetics Pharmaceutical Track & Trace System (ITS) 15

LEGISLATION Harmonization with EU Legislation - 2005 The Turkish MoH has implemented a number of regulations to bring its pharmaceutical laws in line with those in the European Union. 16

PHARMACEUTICAL TRACK AND TRACE SYSTEM (ITS) ITS is a system that traces and checks all processes of medicines with datamatrix at every node from production/importation to the patient. 17

ACTIVITIES FOR RATIONAL USE OF MEDICINES (RUM) IN TURKEY

March 2012 - Rational Drug Use and Drug Supply Management Departmant TMMDA Represantatives İn all cities October 2010 Rational Drug Use (RDU) Branch RUM Activities 20 years 19

7 pharmacist 5 doctor 1 biologist 1 dietician 1 health officer 2 IT expert (engineer) RATIONAL DRUG USE UNIT 20

Aim Cooperation and coordination for all the stakeholders for activities for rational drug use, Change the behaviors of all stakeholders in drug use Objective RDU NATIONAL ACTION PLAN 2014-2017 Complete and strenghten restructuring in order to conduct activities and raise awareness about RUM 21

RDU NATIONAL ACTION PLAN 2014-2017 STAKEHOLDERS PHSYICIANS PHARMACIST HEALTH PROFESSIONALS PUBLIC DRUG INDUSTRY 22

RDU NATIONAL ACTION PLAN 2014-2017 ( 6 TITLES / 20 STRATEGIC OBJECTIVES / 99 ACTIONS ) A. RDU STRUCTURING D. ALLIED HEALTH PERSONNEL o 5 actions were planned under 1 Strategic Target Title o 12 actions were planned under 3 Strategic Objective Title.. Strenghtening RDU structuring: 5 actions Promotion: 4 action Education: 7 actions Monitoring-Evaluation: 1 actions Administrative Arrangement and Planning: 0 action B. PHYSICIANS E. PUBLIC o 29 actions were planned under 4 Strategic Objective Title. o 23 actions were planned under 4 Strategic Objective Title.. Promotion: 6 actions Promotion: 12 actions Education: 11 actions Education: 9 actions Monitoring-Evaluation: 10 actions Monitoring-Evaluation: 1 action Administrative Arrangement and Planning: 2 actions Administrative Arrangement and Planning: 1 action C. PHARMACISTS F. PHARMACEUTICAL INDUSTRY o 17 actions were planned under 4 Strategic Target Title. o 13 actions were planned under 4 Strategic Objective Titles. Promotion: 4 actions Tanıtım: 4 faaliyet Education: 9 actions Promotion: 4 actions Monitoring-Evaluation: 1 actions Monitoring-Evaluation: 3 actions Administrative Arrangement and Planning: 3 actions Administrative Arrangement and Planning: 5 actions 23

ACTIVITIES FOR RUM IN TURKEY-1 Education for representatives in all cities What is Rational Use of Medicines? The Action Plan Aims and responsibilities for representatives National Meeting for RUM Representatives 24

ACTIVITIES FOR RUM IN TURKEY -2 Drug utilization data with ATC/DDD Assessment and Education Meetings on different cities 25

ACTIVITIES FOR RUM IN TURKEY -3 Drug Industry Represantatives education Cooperation with international organisations RDU bulletin Prescription Information System (PIS) 26

PRESCRIPTION INFORMATION SYSTEM (PIS) Started in 2009 Financily supported by World Bank Collects data from family physicians and specialist physicians prescriptions Integrated with the e-prescription system PIS aims to; Monitor and evaluate physicians prescription behaviour. Maintains data feedback to physicians (individual data). 27

STATISTICS PROVIDED BY PIS PIS maintains 4 basic data support; Statistics of individual physicians Statistics for individual health care facilities Trend analysis of provinces Statistics of provinces or whole country 28

29

According to the PIS data; AN EXPERIENCE - GAZIANTEP Percentage of prescriptions that includes antibiotic in Turkey was %34.94 in 2011, %33.99 in 2012 But Gaziantep was the top city prescribing antibiotics with %57.58 in 2011, %55.49 in 2012 Gaziantep was choosen as a pilot area to search the reason for irrational drug use especially antibiotics 30

WHAT DID WE DO IN GAZIANTEP? July 5, 2013 - Meeting with 25 family physicians and directors of Health Institutions of Gaziantep September 23-25, 2013 - Meeting with family physicians, pharmacists and the member of hospital infection committies February 21-22, 2014 - Meeting with pharmacists, subject «Rational Use of Antibiotics» August 2014 Meeting with family physicians and specialist physicians «Rational Use of Antibiotics» 31

RESULT 2012 2013 Months 2012 2013 Differences % Differences October %57.32 %49.61-7,71-13,45 November %59.15 %49.71-9,44-15,95 December %62.06 %55.94-6,12-9,86 32

NO ACTION TODAY NO CURE TOMORROW!!! 33

CONTACT US Adress : Söğütözü Mahallesi 2176. Sokak No:5 06520 Çankaya/ANKARA - TURKEY Phone : +90 312 218 30 00 Web site : www.titck.gov.tr www.akilciilac.gov.tr E-mail : melda.ciba@titck.gov.tr gulsen.oner@titck.gov.tr 34

THANK YOU 35

BON APPETIT 36